HER2-TARGETED THERAPIES

A pooled analysis of T-DM1 trials involving patients with advanced HER2+ breast cancer reported a low incidence of cardiac events and resolution of cardiac events in 79% of patients after treatment discontinuation, but the study demonstrated that patient age 65 years or older and baseline left ventricular ejection fraction lower than 55% are risk factors for cardiac events among patients receiving T-DM1.